Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
For more than 20 years, steady progress has been made along the road to clinical trial transparency. What started with steps taken by medical journals, including disclosure of trial funding, disclosure of authors’ conflicts of interest, publication of trial protocols, and statements of authors’ contributions, has been strengthened by recent advances to require publicly accessible clinical trial registration and results reporting. Encouragingly, progress continues to be made, as there is now considerable momentum toward clinical trial data sharing. Each of these steps was taken with the intention to reduce the potential for bias in the peer-reviewed literature, mitigating problems such as selective publication and selective outcome reporting or guest authorship and ghostwriting and ensuring that research findings are fully disseminated, fairly and objectively, in a way that allows an informed assessment of the evidence.
Ross JS. Confronting Bias. JAMA Intern Med. 2015;175(2):307. doi:10.1001/jamainternmed.2014.6933